We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · January 21, 2019

Health-Related Quality of Life With Abiraterone Plus Prednisone vs Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer

European Urology

 

Additional Info

Disclosure statements are available on the authors' profiles:

European Urology
Health-Related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer: Results From a Phase II Randomized Trial
Eur Urol 2018 Dec 24;[EPub Ahead of Print], DJ Khalaf, K Sunderland, BJ Eigl, CK Kollmannsberger, N Ivanov, DL Finch, C Oja, J Vergidis, M Zulfiqar, ME Gleave, KN Chi

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Advanced Prostate Cancer Center of Excellence

Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.


Further Reading